Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.53 |
| ▸ | CXCR5 | P32302 | 18/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29707280 | 1.00 | GHSR (0.53) | GHSRCXCR5EPHX2 | |
| SCHEMBL5404964 | 0.93 | GHSR (0.47) | GHSRCXCR5EPHX2 | |
| SCHEMBL29715495 | 0.92 | GHSR (0.63) | GHSRCXCR5EPHX2 | |
| SCHEMBL18614234 | 0.92 | GHSR (0.63) | GHSRCXCR5EPHX2 | |
| SCHEMBL2813574 | 0.92 | GHSR (0.63) | GHSRCXCR5EPHX2 | |
| SCHEMBL5393170 | 0.89 | CXCR5 (0.50) | GHSRCXCR5 | |
| SCHEMBL5390112 | 0.88 | CXCR5 (0.46) | GHSRCXCR5 | |
| SCHEMBL5034413 | 0.87 | GHSR (0.52) | GHSREPHX2 | |
| SCHEMBL5416762 | 0.87 | GHSR (0.52) | GHSREPHX2 | |
| SCHEMBL5413304 | 0.84 | GHSR (0.41) | GHSRCXCR5EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12215173-B2 | Kappa opioid receptor peptide amide ligands | HUMANWELL PHARMACEUTICAL US, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| WO-2024076155-A1 | NOVEL COMPOUND AS YEATS DOMAIN INHIBITOR | 노보렉스 주식회사 | 2024-04-11 | — | — | WO | disclosed |
| US-11845724-B2 | USP30 inhibitors and uses thereof | VINCERE BIOSCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-115038688-A | USP30 inhibitors and uses thereof | 文森雷生物科学股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-4028385-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-114615976-A | Kappa opioid receptor peptide amide agonists | 人福医药美国公司 | 2022-06-10 | — | — | CN | disclosed |
| EP-3383867-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2021-04-14 | — | — | EP | disclosed |
| WO-2021050992-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2007005491-A1 | HYDRAZIDE CONJUGATES AS IMAGING AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
| US-20060223830-A1 | Indanyl-piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-05 | — | — | US | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2005123770-A1 | MEDIATORS OF REVERSE CHOLESTEROL TRANSPORT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | AVANIR PHARMACEUTICALS (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| US-20050085517-A1 | Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative | LES LABORATOIRES SERVIER (FR) | 2005-04-21 | — | — | US | disclosed |
| WO-2003057722-A2 | CYCLIC TETRAPEPTIDE COMPOUND AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
| WO-1998051687-A1 | PIPERIDINO DERIVATIVES WHICH PROMOTE GROWTH HORMONE RELEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119245-A1 | GlyT2 modulators | GLRB, GLRA1, GLRA2 | GHSR 877/4885CXCR5 4813/4885EPHX2 3746/4885 |
| US-20060223830-A1 | Indanyl-piperazine compounds | HTR4, NR4A1, NR4A3 | GHSR 415/4885CXCR5 1103/4885EPHX2 2778/4885 |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | CETP, LDLR, NPC1L1 | GHSR 2761/4885CXCR5 2156/4885EPHX2 1285/4885 |
| US-20050085517-A1 | Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative | ARGLU1, PNISR, ATIC | GHSR 183/4885CXCR5 721/4885EPHX2 2941/4885 |
| US-12215173-B2 | Kappa opioid receptor peptide amide ligands | OPRK1, OPRL1, OPRD1 | GHSR 388/4885CXCR5 311/4885EPHX2 2669/4885 |
| US-11845724-B2 | USP30 inhibitors and uses thereof | USP30, USP28, USP1 | GHSR 3300/4885CXCR5 4588/4885EPHX2 3364/4885 |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | GHSR 3300/4885CXCR5 4588/4885EPHX2 3364/4885 |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | GHSR 3300/4885CXCR5 4588/4885EPHX2 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.